Claims
- 1. A pharmaceutical composition comprising (a) carvedilol or a pharmaceutically acceptable salt thereof and (b) one or more pharmaceutically acceptable adjuvants, wherein the carvedilol or salt thereof is distributed in the adjuvant(s), as a molecular dispersion in a concentration above 5% (wt/wt).
- 2. The pharmaceutical composition according to claim 1, which is a solid or semi-solid solution.
- 3. The pharmaceutical composition according to claim 2, wherein one or more adjuvants which are not surface-active are present.
- 4. The pharmaceutical composition according to claim 3, wherein polyethylene glycol is present as an adjuvant which is not surface active.
- 5. The pharmaceutical composition according to claim 4, wherein the polyethylene glycol has a molecular weight of 1,000 to 20,000.
- 6. The pharmaceutical composition according to claim 5, wherein the polyethylene glycol has a molecular weight of 4,000 to 10,000.
- 7. The pharmaceutical composition according to claim 3, wherein a sugar substitute is present as an adjuvant which is not surface active.
- 8. The pharmaceutical composition according to claim 7, wherein isomalt is present as the sugar substitute.
- 9. The pharmaceutical composition according to claim 2, wherein one or more non-ionic tensides are present as an adjuvant.
- 10. The pharmaceutical composition according to claim 9, wherein a polyoxyethylene-polyoxypropylene copolymer is present as a non-ionic tenside.
- 11. The pharmaceutical composition according to claim 9, wherein a polyoxyethylene stearate is present as a non-ionic tenside.
- 12. The pharmaceutical composition according to claim 2, wherein the solution comprises one or more adjuvants which is non-surface active and one or more adjuvants which is a non-ionic tenside.
- 13. The pharmaceutical composition according to claim 12, wherein the ratio of adjuvants which are not surface active to non-ionic tensides lies between 1000:1 and 1:1.
- 14. The pharmaceutical composition according to claim 13, wherein the ratio of adjuvants which are not surface active to non-ionic tensides lies between 100:1 and 10:1.
- 15. The according to claim 14, wherein polyethylene glycol is present as an adjuvent that is not surface active and polyoxyethylene-polyoxypropylene copolymer is present as a non-ionic tenside.
- 16. The pharmaceutical composition according to claim 1, wherein the carvedilol concentration lies between 5% (wt./wt.) and 60% (wt.wt.).
- 17. The pharmaceutical composition according to claim 16, wherein the carvedilol concentration lies between 10% (wt./wt.) and 40% (wt.wt.).
- 18. The pharmaceutical composition according to claim 1, further comprising highly dispersed silicon dioxide.
- 19. A pharmaceutical composition comprising (a) carvedilol or a pharmaceutically acceptable salt thereof, in a concentration of between 10-20% (wt./wt.), (b) polyethylene glycol in a concentration of between 65-85% (wt./wt.), (c) polyoxyethylene-polyoxypropylene copolymer in a concentration of between 1-10% (wt./wt.) and (d) highly dispersed silicon dioxide in a concentration of between 0.1-10% (wt./wt.).
- 20. A composition in unit dosage form comprising (a) a solution containing (i) as a pharmaceutically active ingredient carvedilol or a pharmaceutically acceptable salt thereof and (ii) one or more pharmaceutically acceptable adjuvants, wherein the active ingredient is distributed in the adjuvant(s) as a molecular dispersion in a concentration above 5% (wt./wt. of the solution), and (b) one or more additional pharmaceutically acceptable adjuvants which adjuvants control release of the active ingredient upon administration, said active ingredient being present in said composition in an amount of from about 1 mg to 50 mg.
- 21. The composition according to claim 20, wherein 95% of the active ingredient is released upon administration in 2 to 24 hours.
- 22. The composition according to claim 21, which is a solid form.
- 23. The composition according to claim 22, which is an oral form.
Priority Claims (1)
Number |
Date |
Country |
Kind |
00107093.7 |
Apr 2000 |
EP |
|
RELATED APPLICATIONS
[0001] This application is a continuation of 09/817,308, filed on Mar. 26, 2001.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09817308 |
Mar 2001 |
US |
Child |
10214697 |
Aug 2002 |
US |